• SPX
  • $5,948.71
  • 0.53 %
  • $31.60
  • DJI
  • $43,870.35
  • 1.06 %
  • $461.88
  • N225
  • $38,283.78
  • 0.68 %
  • $257.68
  • FTSE
  • $8,149.27
  • 0.79 %
  • $64.20
  • IXIC
  • $18,972.42
  • 0.03 %
  • $6.28
BriaCell Therapeutics Corp. (BCTXW) Stock Price, News & Analysis

BriaCell Therapeutics Corp. (BCTXW) Stock Price, News & Analysis

Currency in USD Disclaimer

$0.31

$0.01

(2.73%)

Day's range
$0.29
Day's range
$0.42
50-day range
$0.1351
Day's range
$0.5
  • Country: CA
  • ISIN: CA10778Y1126
52 wk range
$0.29
Day's range
$0.42
  • CEO: Dr. William V. Williams M.D.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -39.43
  • Piotroski Score 0.00
  • Grade N/A
  • Symbol (BCTXW)
  • Company BriaCell Therapeutics Corp.
  • Price $0.31
  • Changes Percentage (2.73%)
  • Change $0.01
  • Day Low $0.29
  • Day High $0.42
  • Year High $0.42

BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers. The company has a collaboration with Incyte Corporation to evaluate combination of the Bria-IMT. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 04/29/2023
  • Fiscal Year End N/A

  • Average Stock Price Target $0.00
  • High Stock Price Target $0.00
  • Low Stock Price Target $0.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) $0.00
  • Trailing P/E Ratio N/A
  • Forward P/E Ratio N/A
  • P/E Growth N/A
  • Net Income $-4,791,466

Income Statement

Quarterly

Annual

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

BriaCell Therapeutics Corp. Frequently Asked Questions

  • What is the BriaCell Therapeutics Corp. stock price today?

    Today's price of BriaCell Therapeutics Corp. is $0.31 — it has increased by +2.73% in the past 24 hours. Watch BriaCell Therapeutics Corp. stock price performance more closely on the chart.

  • Does BriaCell Therapeutics Corp. release reports?

    Yes, you can track BriaCell Therapeutics Corp.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the BriaCell Therapeutics Corp. stock forecast?

    Watch the BriaCell Therapeutics Corp. chart and read a more detailed BriaCell Therapeutics Corp. stock forecast to see what analysts suggest you do with its shares.

  • What is BriaCell Therapeutics Corp. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by BriaCell Therapeutics Corp. stock ticker.

  • How to buy BriaCell Therapeutics Corp. stocks?

    Like other stocks, BCTXW shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is BriaCell Therapeutics Corp.'s EBITDA?

    BriaCell Therapeutics Corp. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in BriaCell Therapeutics Corp.’s financial statements.

  • What is the BriaCell Therapeutics Corp.'s net income ratio for the financial year 2024?

    The net income ratio for the financial year 2024 is 0, which equates to approximately 0.00%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in BriaCell Therapeutics Corp. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including BriaCell Therapeutics Corp.'s financials relevant news, and technical analysis. BriaCell Therapeutics Corp.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for BriaCell Therapeutics Corp. stock currently indicates a “sell” signal. For more insights, review BriaCell Therapeutics Corp.’s technical analysis.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.